Department of Hematology, Faculty of Medicine and Health Sciences, Sana'a University, Sana'a, Yemen.
Department of Clinical Pharmacology, Faculty of Medicine and Health Sciences, Sana'a University, Sana'a, Yemen.
Hemoglobin. 2020 Mar;44(2):104-108. doi: 10.1080/03630269.2020.1754232. Epub 2020 Apr 20.
The response to hydroxyurea (HU) therapy of 44 Yemeni transfusion-dependent β-thalassemia (β-thal) patients in Sana'a City, Yemen, was assessed. All patients were treated with a dose of 15 mg/kg/day HU for 4-10 months. Thirty-six patients responded partially to HU with clinical improvement of anemia and extramedullary hematopoiesis features, whereas the rest remained almost at the same baseline levels of transfusion dependency. Hydroxyurea was shown to have a variable favorable effect on β-thal in Yemeni patients. Further study is required to identify the various response factors to HU therapy, as well as to investigate its long-term efficacy and safety.
对也门萨那市 44 名依赖输血的β-地中海贫血（β-地中海贫血）患者接受羟脲（HU）治疗的反应进行了评估。所有患者均接受 15mg/kg/天 HU 治疗 4-10 个月。36 名患者对 HU 治疗有部分反应，贫血和骨髓外造血特征得到改善，而其余患者仍几乎处于相同的输血依赖基线水平。HU 对也门患者的β-地中海贫血有不同的有利影响。需要进一步研究以确定 HU 治疗的各种反应因素，并研究其长期疗效和安全性。
